Show Notes
In this episode, Meron Gribetz discusses the unmet need in current depression treatment and how Inner Cosmos is developing an implanted alternative. He explains how the device works, why brain stimulation could reshape psychiatric treatment, and how questions of agency, privacy, and control become increasingly important as BCIs grow more invasive.
More from Synaptech News
In this episode, Lucas Scherdel discusses co-founding Connectome to make brain function easier to measure and track over time. He explains how the company combines brain scans with wearable data to explore how lifestyle affects the brain.
In this episode, Hamed Bahmani discusses founding three neurotechnology companies. He explains the thinking behind Dopavision and Nuuron, then introduces Insellar’s early work on an implant designed to stimulate deep brain structures as a potential treatment for depression.
In this episode, John Dyer discusses how Cumulus Neuroscience is moving brain measurement for dementia beyond the clinic and into patients’ homes. He explains how repeated measurements of EEG, cognition, sleep, and behavior could offer a more complete picture of brain health.
In this episode, Amy Kruse discusses her vision for investing in a broader neurotech toolbox. She explains how to separate credible brain-health products from marketing hype, and how neuromodulation could eventually allow us to shape states such as sleep, focus, and mood.
In this episode, Adam Caplan shares how he went from a career in Wall Street and tech entrepreneurship to building Jump Space Ventures, a specialist neurotech venture fund. He explains what drew him into neurotech, why brain-computer interfaces are attracting so much attention, and what investors are really looking for in this fast-moving space.